Ovarian cancer treatment stratification using ex vivo drug sensitivity testing

Ines Lohse; Diana J. Azzam; Hassan Al-Ali; Claude Henry Volmar; Shaun P. Brothers; Tan A. Ince; Claes Wahlestedt

doi:10.21873/anticanres.13558

Ovarian cancer treatment stratification using ex vivo drug sensitivity testing

Ines Lohse, Diana J. Azzam, Hassan Al-Ali, Claude Henry Volmar, Shaun P. Brothers, Tan A. Ince, Claes Wahlestedt

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Background: Treatment options for patients with platinum-resistant ovarian cancer are generally palliative in nature and rarely have realistic potential to be curative. Because many patients with recurrent ovarian cancer receive aggressive chemotherapy for prolonged periods, sometimes continuously, therapy-related toxicities are a major factor in treatment decisions. The use of ex vivo drug sensitivity screens has the potential to improve the treatment of patients with platinum-resistant ovarian cancer by providing personalized treatment plans and thus reducing toxicity from unproductive therapy attempts. Materials and Methods: We evaluated the treatment responses of a set of six early-passage patient-derived ovarian cancer cell lines towards a set of 30 Food and Drug Administration-approved chemotherapy drugs using drug-sensitivity testing.

Original language	English (US)
Pages (from-to)	4023-4030
Number of pages	8
Journal	Anticancer research
Volume	39
Issue number	8
DOIs	https://doi.org/10.21873/anticanres.13558
State	Published - 2019

Keywords

Ex vivo drug sensitivity screening
Ovarian cancer
Precision medicine

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.21873/anticanres.13558

Fingerprint Dive into the research topics of 'Ovarian cancer treatment stratification using ex vivo drug sensitivity testing'. Together they form a unique fingerprint.

Cite this

@article{00f599a9ee29432d9851afd40ab7c06d,

title = "Ovarian cancer treatment stratification using ex vivo drug sensitivity testing",

abstract = "Background: Treatment options for patients with platinum-resistant ovarian cancer are generally palliative in nature and rarely have realistic potential to be curative. Because many patients with recurrent ovarian cancer receive aggressive chemotherapy for prolonged periods, sometimes continuously, therapy-related toxicities are a major factor in treatment decisions. The use of ex vivo drug sensitivity screens has the potential to improve the treatment of patients with platinum-resistant ovarian cancer by providing personalized treatment plans and thus reducing toxicity from unproductive therapy attempts. Materials and Methods: We evaluated the treatment responses of a set of six early-passage patient-derived ovarian cancer cell lines towards a set of 30 Food and Drug Administration-approved chemotherapy drugs using drug-sensitivity testing.",

keywords = "Ex vivo drug sensitivity screening, Ovarian cancer, Precision medicine",

author = "Ines Lohse and Azzam, {Diana J.} and Hassan Al-Ali and Volmar, {Claude Henry} and Brothers, {Shaun P.} and Ince, {Tan A.} and Claes Wahlestedt",

note = "Funding Information: SB received support from the National Institutes of Health (R01NS092671 and R01MH110441) and the Jay Weiss Institute for Health Equity. CW{\textquoteright}s laboratory is currently funded by NIH grants DA035592, DA035055 and AA023781, and Florida Department of Health grants 6AZ08 and 7AZ26. HAA received support from the National Institutes of Health (NS100531) and the Wallace H. Coulter Foundation. TAI is supported by grants from Breast Cancer Research Foundation (BCRF), NCI (R33CA214310) and Department of Defense (DoD) Ovarian Cancer Research Program (OCRP) grant (OC130649). Funding Information: Some of this work was supported by the Sylvester Cancer Center Molecular Therapeutics Shared Resource (MTSR).",

year = "2019",

doi = "10.21873/anticanres.13558",

language = "English (US)",

volume = "39",

pages = "4023--4030",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "8",

}

TY - JOUR

T1 - Ovarian cancer treatment stratification using ex vivo drug sensitivity testing

AU - Lohse, Ines

AU - Azzam, Diana J.

AU - Al-Ali, Hassan

AU - Volmar, Claude Henry

AU - Brothers, Shaun P.

AU - Ince, Tan A.

AU - Wahlestedt, Claes

N1 - Funding Information: SB received support from the National Institutes of Health (R01NS092671 and R01MH110441) and the Jay Weiss Institute for Health Equity. CW’s laboratory is currently funded by NIH grants DA035592, DA035055 and AA023781, and Florida Department of Health grants 6AZ08 and 7AZ26. HAA received support from the National Institutes of Health (NS100531) and the Wallace H. Coulter Foundation. TAI is supported by grants from Breast Cancer Research Foundation (BCRF), NCI (R33CA214310) and Department of Defense (DoD) Ovarian Cancer Research Program (OCRP) grant (OC130649). Funding Information: Some of this work was supported by the Sylvester Cancer Center Molecular Therapeutics Shared Resource (MTSR).

PY - 2019

Y1 - 2019

N2 - Background: Treatment options for patients with platinum-resistant ovarian cancer are generally palliative in nature and rarely have realistic potential to be curative. Because many patients with recurrent ovarian cancer receive aggressive chemotherapy for prolonged periods, sometimes continuously, therapy-related toxicities are a major factor in treatment decisions. The use of ex vivo drug sensitivity screens has the potential to improve the treatment of patients with platinum-resistant ovarian cancer by providing personalized treatment plans and thus reducing toxicity from unproductive therapy attempts. Materials and Methods: We evaluated the treatment responses of a set of six early-passage patient-derived ovarian cancer cell lines towards a set of 30 Food and Drug Administration-approved chemotherapy drugs using drug-sensitivity testing.

AB - Background: Treatment options for patients with platinum-resistant ovarian cancer are generally palliative in nature and rarely have realistic potential to be curative. Because many patients with recurrent ovarian cancer receive aggressive chemotherapy for prolonged periods, sometimes continuously, therapy-related toxicities are a major factor in treatment decisions. The use of ex vivo drug sensitivity screens has the potential to improve the treatment of patients with platinum-resistant ovarian cancer by providing personalized treatment plans and thus reducing toxicity from unproductive therapy attempts. Materials and Methods: We evaluated the treatment responses of a set of six early-passage patient-derived ovarian cancer cell lines towards a set of 30 Food and Drug Administration-approved chemotherapy drugs using drug-sensitivity testing.

KW - Ex vivo drug sensitivity screening

KW - Ovarian cancer

KW - Precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85070597348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070597348&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13558

DO - 10.21873/anticanres.13558

M3 - Article

C2 - 31366484

AN - SCOPUS:85070597348

VL - 39

SP - 4023

EP - 4030

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 8

ER -